Capsule

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Retrieved on: 
Tuesday, March 26, 2024
OCT, Optical coherence tomography, Patent, Multiple sclerosis, Capsule, Tablet, Code, MD, SPRINT, MPH, Tokyo Stock Exchange, Pharmaceutical industry

Once issued, this patent is expected to expire no earlier than October 2039.

Key Points: 
  • Once issued, this patent is expected to expire no earlier than October 2039.
  • The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.
  • The allowed claims specifically cover both primary progressive multiple sclerosis and secondary progressive multiple sclerosis.
  • Previously, we reported positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 in progressive multiple sclerosis.

AustinPx Invests in Pharmaceutics and Manufacturing Capabilities to Accelerate Drug Development

Retrieved on: 
Monday, April 8, 2024
Health, Manufacturing, Health Technology, Clinical Trials, Other Manufacturing, Pharmaceutical, Biotechnology, CDMO, Growth, Capsule, Risk, Rheometer, Acquisition, FT4, Senior, Investment, Clinical trial, API, Korsch, Fine chemical

The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.

Key Points: 
  • The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
  • The technology enables rapid transition into first-in-human clinical trial material manufacturing, while also reducing the cost of drug product development.
  • “These tools enable scientists and engineers to rapidly develop life-changing therapies with enhanced data and quality.”
    The expanded capabilities are now available for use.
  • The additional capabilities mark another milestone in the growth of AustinPx’s formulation development and manufacturing offerings, as the Company continues to position itself as a leading CDMO in the pharmaceutical industry.

Milan Salone Del Mobile 2024: illycaffè to feature at the design industry's most important international event

Retrieved on: 
Monday, April 8, 2024
Vanity Fair, Partner, Capsule, Recycling, Coffee, Beauty, Research, Artificial intelligence, Antonio Citterio, Stampa, Kartell, Creativity, Future, Via Monte Napoleone, Illy, Fashion design

MILAN, April 8, 2024 /PRNewswire/ -- illycaffè is getting ready for its star turn at the Milan Design Week.

Key Points: 
  • MILAN, April 8, 2024 /PRNewswire/ -- illycaffè is getting ready for its star turn at the Milan Design Week.
  • Those attending will find the global leader in high-quality sustainable coffee both at the Milan Furniture Fair and around the city at key events that celebrate the collision of beauty, innovation, and sustainability.
  • This theme is perfectly in line with the chosen theme for the 62nd edition of the fair: "Materia Natura".
  • Indeed, the press office will feature the chairs and the new A.I.

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Retrieved on: 
Monday, March 18, 2024
Entrepreneurship, Capsule, Patient, Food and Drug Administration, Rosacea, NDA, Red, Minocycline, Erythema, Food, Marketing, FDA, CEA, Physician, IGA, PDUFA, Pharmaceutical industry

The FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024.

Key Points: 
  • The FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024.
  • The Phase 3 clinical trials achieved all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues.
  • DFD-29 demonstrated statistically significant superiority over both the current standard-of-care treatment, Oracea® 40 mg capsules, and placebo for Investigator’s Global Assessment (IGA) treatment success as well as the reduction in the total inflammatory lesion count in both studies.
  • For the secondary endpoint evaluating erythema (redness) associated with rosacea, DFD-29 showed a statistically significant reduction in Clinician’s Erythema Assessment (CEA) compared to placebo in both clinical trials.”

NatureWorks and IMA Announce Turn-Key Compostable Coffee Pod Solution Compatible for North America

Retrieved on: 
Thursday, April 4, 2024
Technology, Science, Agriculture, Natural Resources, Textiles, Oil, Gas, Packaging, Alternative Energy, Engineering, Energy, Other Science, Chemicals, Plastics, Food, Beverage, Manufacturing, Retail, Food Tech, Environment, Marketing strategy, NatureWorks, PLA, Ingeo, Taste, AMI, Biopolymer, Capsule, Filter, Partnership, Coffee, Compost, IMA, Wageningen University & Research, PP, Keurig Dr Pepper, DIN, Biodiversity, Methane, Multimedia, Soil

NatureWorks , a leading manufacturer of polylactic acid (PLA) biopolymers made from renewable resources, has optimized a compostable coffee pod solution compatible with Keurig® brewers for the North American market.

Key Points: 
  • NatureWorks , a leading manufacturer of polylactic acid (PLA) biopolymers made from renewable resources, has optimized a compostable coffee pod solution compatible with Keurig® brewers for the North American market.
  • The partnership between NatureWorks and IMA Coffee began in April 2021 with accelerated testing announced in February of 2022.
  • IMA Coffee and NatureWorks presented on this new coffee pods solution at the AMI Single-Serve Capsules conference held from March 19-20 in Boston, MA.
  • View the full release here: https://www.businesswire.com/news/home/20240404501499/en/
    Every IMA Coffee pod filling and sealing machine can handle compostable coffee pods made from Ingeo™ PLA biopolymer.

Global Immune Health Supplements Outlook Report 2024: Market to Reach $34.73 Billion by 2028 with Amway, Bayer, DSM, Glanbia, Herbalife Nutrition, and Nutramax Laboratories Dominating - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 28, 2024
Vitamins, Supplements, Health, Capsule, Dicarboxylic acid, Attention, Bayer, Vitamin, Growth, Prevalence, Vitamin D, Infection, Amway, Dietary supplement, Printing, Probiotic, COVID-19, Zinc, DSM, Tablet, Calcium, Pharmacy, Selenium, Ageing, Pregnancy, Mineral, Protein, Mineral deficiency, Woman, Nutritional science, Immunity, Wound healing, Iron, Nutraceutical, Herbalife, Herbal, Supermarket

The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach $34.73 billion by 2028, growing at a CAGR of 8.92%

Key Points: 
  • The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach $34.73 billion by 2028, growing at a CAGR of 8.92%
    The global immune health supplements market is witnessing several dynamic changes after the Coronavirus surge worldwide.
  • In the global immune health supplements market, several leading domestic, national, and international vendors are present.
  • North America accounted for the highest global immune health supplements market share, accounting for over 33% in 2022.
  • High Demand for Immune Health Supplements with Zinc, Vitamin C & D, and Curcumins
    In the immune health supplements market, vitamin C, vitamin D, zinc, and curcumins are the most used and suggested ingredients for immune health.

Sexual Health Supplement Market Size, Share & Trends Analysis Report 2024: Natural Ingredients Lead Market Amid Preference for Organic Products - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Vitamins, Supplements, Other Health, Other Retail, Health, Retail, Dicarboxylic acid, Tablet, Prevalence, Human, Erectile dysfunction, Capsule, Application, COVID-19, Anxiety, Synthetic, NIH, King's College London, Parity, Nature, Safety, ED, Market, Dietary supplement

As per King's College London, ED is estimated that by 2025, 322 million men worldwide are expected to be affected by it.

Key Points: 
  • As per King's College London, ED is estimated that by 2025, 322 million men worldwide are expected to be affected by it.
  • Government-supported sexual health programs indeed have a significant impact on the market.
  • These programs help to increase awareness about sexual health issues, promote safe sex practices and encourage people to take proactive steps to maintain their sexual health.
  • For instance, Australia Department of Health has "Healthysexual" program, which raise awareness about sexual health.

Nintendo Celebrates MAR10 Day With Games, Movie News and a Variety of Mario-Themed Activities

Retrieved on: 
Monday, March 11, 2024
Toys, Entertainment, Retail, Other Entertainment, Film & Motion Pictures, Electronic Games, Online, Dark, Dark Moon, Maker, Cloud, Piranha Plant, Mario Kart 8, RPG, Super Mario, Friends, Paper, Smartphone, Target, Grand Champion, Nintendo eShop, HOPE, Amazon, Capsule, Golf, Lego Super Mario, GameCube, Purchasing, Internet, Mario Tennis, Game Boy, Travel, Virus, Super Mario Bros., Dark moon, Nintendo Switch Lite, Nintendo Switch, News, Fun, GameStop, Nintendo Switch Online, MAR10, Club, Nintendo Account, LEGO, Model, Multimedia, HD, Family, Super Mario Party, Tennis, Human, Video game

View the full release here: https://www.businesswire.com/news/home/20240311148081/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240311148081/en/
    Paper Mario: The Thousand-Year Door arrives on the Nintendo Switch family of systems on May 23.
  • The witty and whimsical RPG arrives on the Nintendo Switch system twenty years after its original debut on Nintendo GameCube.
  • * In honor of MAR10 Day, Nintendo is offering twice the fun with the Nintendo Switch Online 14-Day Free Trial Membership (typically 7 days), available now through March 17 on My Nintendo .
  • Watch the Super Mario Bros. Movie and Check Out the Companion Digital Guidebook – What better way to celebrate MAR10 Day than to watch The Super Mario Bros. Movie?

SYNPET to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024

Retrieved on: 
Wednesday, April 3, 2024
Health, Growth, Capsule, Probiotic, NGS, Research, Lactic acid, Interview, Kansas City Convention Center, DNA sequencing, Immunity, Facial muscles, Fermentation, Pet, Aggression

TAIPEI, April 3, 2024 /PRNewswire/ -- SYNPET, a subsidiary brand of SYNBIO TECH, a leading lactobacillus manufacturer based in Taiwan, is proud to announce its participation at the upcoming Petfood Forum 2024.

Key Points: 
  • TAIPEI, April 3, 2024 /PRNewswire/ -- SYNPET, a subsidiary brand of SYNBIO TECH, a leading lactobacillus manufacturer based in Taiwan, is proud to announce its participation at the upcoming Petfood Forum 2024.
  • At Petfood Forum 2024, SYNPET will showcase its headlining product:
    GABA 20: A postbiotic designed for pets to boost immunity, reduce stress and aggressive behavior.
  • "We are thrilled to participate in Petfood Forum 2024 and introduce our innovative probiotic solutions to the pet food industry," said Tammy Chang, Vice President of SYNBIO TECH.
  • For media inquiries or to schedule an interview with SYNPET representatives at Petfood Forum 2024, please contact:

Zero Gravity Corporation Announces Appointment of New CEO, Kevin Sproge

Retrieved on: 
Tuesday, April 2, 2024
Astronaut, Growth, Blue Origin, Active duty, Commercial astronaut, CAPCOM, Mission control center, Gravity, Weightlessness, Certification, Engineering, New Shepard, NS-16, Flight controller, Capsule, Crewman, Mission assurance, Zero Gravity Corporation, Management

EXPLORATION PARK, Fla., April 2, 2024 /PRNewswire-PRWeb/ -- Zero Gravity Corporation ("Zero-G"), the world leader in zero gravity flights, is pleased to announce the appointment of Kevin Sproge as its Chief Executive Officer. Sproge is a former U.S. Navy Test Pilot who retired from Active Duty in 2018. His prior roles include Head of Commercial Astronaut Training at Blue Origin and Director of Safety and Mission Assurance for Sierra Space's Space Destinations Business Sector.

Key Points: 
  • Zero Gravity Corporation ("Zero-G"), the world leader in zero gravity flights, is pleased to announce the appointment of Kevin Sproge as its Chief Executive Officer.
  • Sproge is a former U.S. Navy Test Pilot who retired from Active Duty in 2018.
  • EXPLORATION PARK, Fla., April 2, 2024 /PRNewswire-PRWeb/ -- Zero Gravity Corporation ("Zero-G"), the world leader in zero gravity flights, is pleased to announce the appointment of Kevin Sproge as its Chief Executive Officer.
  • Sproge is a former U.S. Navy Test Pilot who retired from Active Duty in 2018.